Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
复制标题
DOI：
10.1016/j.vaccine.2007.02.050
复制
发表时间：
2007-05-16
期刊：
影响因子：
5.5
通讯作者：
Graham, Barney S.
中科院分区：
文献类型：
--
作者：
Catanzaro, Andrew T.;Roederer, Mario;Graham, Barney S.
在15名受试者中进行了开放标签评估，无针递送编码EnvA、EnvB、EnvC和B亚型Gag、Pol和Nef的六质粒HIV-1 DNA疫苗；14人完成了0、1、2个月的疫苗接种计划。细胞内细胞因子染色CD4(+)[13/14(93%)]和CD8(+)[5/14(36%)], 11/14（79%）用ELISpot检测T细胞对hiv特异性肽池的反应。14例中有10例（71%）对Env蛋白有ELISA抗体反应。与四质粒产物相比，Gag和nef特异性T细胞反应得到改善，而env特异性T细胞反应保持不变。该候选疫苗现已进入II期评估阶段。Elsevier Ltd.出版。
Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4(+) [13/14 (93%)] and CD8(+) [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation. Published by Elsevier Ltd.